Fralin Life Science Institute

PDL BioPharma, Inc. today announced that NASDAQ has established November 27, 2009 as the ex-dividend date for its $200 million special dividend to stockholders resulting from the securitization transaction completed on November 2, 2009.

Transcept Pharmaceuticals, Inc. today announced that it is scheduled to meet with the U.S. Food and Drug Administration on January 20, 2010 to discuss the Complete Response Letter regarding the New Drug Application for Intermezzo® .

PALO ALTO, Calif.----StemCells, Inc. announced today that its president and CEO, Martin McGlynn, was recently featured on BioBusiness.TVâ??s â??Stem Cell Reviewâ? discussing the Companyâ??s therapeutic product development programs, including the promise of human neural stem cells and the broad potential application of the Companyâ??s lead product candidate, HuCNS-SC® cells, in a variety of central nervous system disorders.

Amgen was honored with two 2009 Scrip Awards, winning for Best Overall Pipeline and for Best New Drug for Nplate® , at a Nov. 18 ceremony in London.

Poniard Pharmaceuticals today announced the sale of 3,465,878 of its common shares to Azimuth Opportunity Ltd. for gross proceeds of approximately $7.4 million, or approximately $2.15 per share, under its existing committed equity financing facility with Azimuth.

Seattle Genetics Inc. said Monday it will receive $12 million as part of an expanded collaboration with Astellas unit Agensys Inc.

NEWPORT BEACH, Calif. -- BUYINS.NET, www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Hemispherx Biopharma after releasing the latest short sale data to November 20, 2009.

Legendary investor Carl Icahn is known for making headlines with big moves in the market.

BOTHELL, Wash. & SANTA MONICA, Calif.----Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Astellas, announced today an expansion of the companiesâ?? antibody-drug conjugate collaboration.

PALO ALTO, Calif.----StemCells, Inc. announced today that it has commenced patient recruitment for a Phase I clinical trial designed to test the safety and preliminary efficacy of its HuCNS-SC® purified human neural stem cells in Pelizaeus-Merzbacher Disease , a neurological disorder that primarily afflicts children.

BROOMFIELD, Colo.----ARCA biopharma, Inc. today announced that the U.S. Food and Drug Administration has designated as a Fast Track development program the investigation of GencaroTM, the Companyâ??s investigational, pharmacologically unique beta-blocker and mild vasodilator, for the reduction of cardiovascular mortality and cardiovascular hospitalizations in a genotype-defined heart failure population.